The soluble form of CD83 is present at elevated levels in a number of hematological malignancies

被引：63

作者：

Hock, BD ^{[1
]}

Haring, LF

Steinkasserer, A

Taylor, KG

Patton, WN

McKenzie, JL

机构：

[1] Christchurch Hosp, Haematol Res Grp, Christchurch, New Zealand

[2] Univ Erlangen Nurnberg, Dept Dermatol, D-8520 Erlangen, Germany

来源：

LEUKEMIA RESEARCH | 2004年 / 28卷 / 03期

关键词：

soluble CD83; leukemia; non-Hodgkin's lymphoma;

D O I：

10.1016/S0145-2126(03)00255-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recombinant forms of soluble CD83 (sCD83) inhibit anti-tumor responses. In this analysis of circulating sCD83 levels we report that although >95% of acute myeloid leukemia (AML) and multiple myeloma (MM) patients have normal or only weakly elevated sCD83 levels, 20% of chronic lymphocytic leukemia (CLL) and 5/7 mantle cell lymphoma (MCL) patients have significantly elevated levels (>1 ng/ml). Isolated CLL cells both weakly expressed membrane CD83 (mCD83), and released sCD83 during in vitro culture. We conclude that malignant cells are a potential source of sCD83 and that it may have functional and/or prognostic significance in hematological malignancies, particularly CLL and MCL. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：237 / 241

页数：5

共 15 条

[1] Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes [J].

Albert, ML ;

Pearce, SFA ;

Francisco, LM ;

Sauter, B ;

Roy, P ;

Silverstein, RL ;

Bhardwaj, N .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (07) :1359-1368

[2] Soluble cytokine receptors [J].

Heaney, ML ;

Golde, DW .

BLOOD, 1996, 87 (03) :847-857

[3] Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients [J].

Hock, BD ;

Patton, WN ;

Budhia, S ;

Mannari, D ;

Roberts, P ;

McKenzie, JL .

LEUKEMIA, 2002, 16 (05) :865-873

[4] A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera [J].

Hock, BD ;

Kato, M ;

McKenzie, JL ;

Hart, DNJ .

INTERNATIONAL IMMUNOLOGY, 2001, 13 (07) :959-967

[5]

Jones SA, 1998, EUR J IMMUNOL, V28, P3514, DOI 10.1002/(SICI)1521-4141(199811)28:11<3514::AID-IMMU3514>3.0.CO

[6]

2-T

[7] The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells [J].

Lechmann, M ;

Krooshoop, DJEB ;

Dudziak, D ;

Kremmer, E ;

Kuhnt, C ;

Figdor, CG ;

Schuler, G ;

Steinkasserer, A .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (12) :1813-1821

[8]

Patton WN, 2002, BLOOD, V100, p750A

[9] SOLUBLE RECEPTORS FOR CYTOKINES AND GROWTH-FACTORS - GENERATION AND BIOLOGICAL FUNCTION [J].

ROSEJOHN, S ;

HEINRICH, PC .

BIOCHEMICAL JOURNAL, 1994, 300 :281-290

[10] Cutting edge:: CD83 regulates the development of cellular immunity [J].

Scholler, N ;

Hayden-Ledbetter, M ;

Dahlin, A ;

Hellström, I ;

Hellström, KE ;

Ledbetter, JA .

JOURNAL OF IMMUNOLOGY, 2002, 168 (06) :2599-2602

← 1 2 →